ipilimumab,nivolumab
bms
[]
 29-mo fu cm648 #1l adv #escc pd-l1+ shows os benefit w/chemo + nivo and nivo/ipi over platinum-based chemo, subgroup analysis show dose-dependent pd-l1 positivity impact on benefit to both chemo-nivo and nivo/ipi in adv escc #gi23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope